Bluebird’s Fast Lyfgenia Launch Was A Year And A Half In The Making; Medicaid Talks Continuing

Zynteglo Build Gives Firm A Leg Up In Sickle Cell Disease

When Zynteglo was approved for beta-thalassemia, bluebird said launch would lay groundwork for sickle cell gene therapy Lyfgenia. The strategy is paying off so far with a fast ramp-up. Outcomes-based contracts for Lyfgenia give payers rebate based on hospitalizations over a three-year period.

DNA helix 3D illustration. Mutations under microscope. Decoding genome.
Bluebird's sickle cell gene therapy Lyfgenia launched in January • Source: Shutterstock

Bluebird bio inc.’s sickle cell disease gene therapy Lyfgenia (lovotibeglogene autotemcel) won US Food and Drug Administration approval on the same day in December as Vertex Pharmaceuticals Incorporated/CRISPR Therapeutics AG’s competing gene-editing medicine Casgevy (exagamglogene autotemcel), but a month later bluebird’s product is in the lead in terms of qualified treatment centers (QTCs) ready to administer the drug and the number of patient lives covered by payers that have agreed to reimburse Lyfgenia’s multimillion-dollar cost.

Key Takeaways

  • Bluebird is in “advanced discussions” with 15 different state Medicaid agencies on Lyfgenia coverage.

The company said when it won FDA approval for its beta-thalassemia gene therapy Zynteglo (betibeglogene autotemcel) in August 2022 that...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Cell & Gene Therapies

More from Advanced Technologies